Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 61 of 1,261
  1. US 12226435

    Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  2. US 12226546

    Polyion complex polypeptide hydrogels and uses thereof

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  3. US 12226423

    Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

    United States Government as represented by the Department of Veterans Affairs Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  4. US 12226476

    Helper epitope peptide and application thereof

    CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  5. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  6. US 12227547

    Modulators of CAS9 polypeptides and methods of use thereof

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  7. US 12226373

    Treatment of fragile X syndrome with cannabidiol

    Harmony Biosciences Management, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  8. US 12226386

    Compositions and methods for treating biofilms

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  9. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  10. US 12226425

    Inhibitors of ARG1 and/or ARG2

    Arcus Biosciences, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  11. US 12226524

    Coated implants for long-term controlled release of antibody therapeutics

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  12. US 12226410

    Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6

    Northwestern University Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  13. US 12226456

    Nasal powder formulation for treatment of hypoglycemia

    Amphastar Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  14. US 12226429

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  15. US 12226491

    Nano-satellite complexes

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  16. US 12227482

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  17. US 12227508

    TGF-Ξ² inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  18. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  19. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  20. US 12226450

    Peptides and methods for treating disease

    The Regents of the University of Colorado, a Body Corporate Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  21. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Inhibrx Biosciences, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  22. US 12227504

    Spirocyclic compounds

    C4 THERAPEUTICS, INC. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  23. US 12227580

    Antigen binding molecules that bind LIGHT

    CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  24. US 12227581

    Anti-BCMA single domain antibodies and application thereof

    SHENZHEN PREGENE BIOPHARMA CO., LTD. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.